Tasquinimod

Pricing Availability   Qty
Cat.No. 7051 - Tasquinimod | C20H17F3N2O4 | CAS No. 254964-60-8
Description: High affinity HDAC4 negative allosteric modulator; also binds S100A9; antiangiogenic
Chemical Name: 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity

High affinity negative allosteric modulator of HDAC4 (Kd = 10 - 30 nM). Binds the regulatory Zn2+ binding domain of HDAC4. Suppresses hypoxia-induced decrease in histone acetylation in human prostate cancer cells in vitro. Also binds S100A9. Antiangiogenic. Inhibits endothelial sprouting in vitro and growth of prostate tumor xenografts in nude mice. Orally bioavailable.

Technical Data

M. Wt 406.36
Formula C20H17F3N2O4
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 254964-60-8
PubChem ID 54682876
InChI Key ONDYALNGTUAJDX-UHFFFAOYSA-N
Smiles COC1=C2C(O)=C(C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)C(=O)N(C)C2=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 40.64 100
ethanol 8.13 20

Preparing Stock Solutions

The following data is based on the product molecular weight 406.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.46 mL 12.3 mL 24.61 mL
5 mM 0.49 mL 2.46 mL 4.92 mL
10 mM 0.25 mL 1.23 mL 2.46 mL
50 mM 0.05 mL 0.25 mL 0.49 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

Isaacs et al (2013) Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 73 1386 PMID: 23149916

Isaacs et al (2014) Anti-cancer potency of Tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget 5 8093 PMID: 25193858


If you know of a relevant reference for Tasquinimod, please let us know.

View Related Products by Product Action

View all Class II HDAC Inhibitors

Keywords: Tasquinimod, Tasquinimod supplier, High, affinity, HDAC4, histone, deacetylase, negative, allosteric, modulators, modulates, NAM, orally, bioavailable, antiangiogenic, binds, S100A9, Class, II, HDACs, 7051, Tocris Bioscience

Citations for Tasquinimod

Citations are publications that use Tocris products.

Currently there are no citations for Tasquinimod. Do you know of a great paper that uses Tasquinimod from Tocris? Please let us know.

Reviews for Tasquinimod

There are currently no reviews for this product. Be the first to review Tasquinimod and earn rewards!

Have you used Tasquinimod?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Epigenetics

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer

Epigenetics in Cancer Poster

Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.